| Cat.No. | Name | Information |
|---|---|---|
| M9199 | Avacopan | Avacopan (CCX168) is a first-in-class, potent, selective and orally available complement 5a receptor (C5aR1 or CD88) antagonist with an IC50 of 0.1 nM. |
| M52861 | N-((Allyloxy)carbonyl)-N-methyl-L-alanine | N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative. |
| M52860 | C5a Receptor agonist, mouse, human | C5a Receptor agonist, mouse, human is a biological active peptide. |
| M52859 | C5a Anaphylatoxin (human) | C5a Anaphylatoxin (human) is a pro-inflammatory peptide and a leukocyte chemoattractant. |
| M49822 | ANX005 | ANX005 is a monoclonal antibody that blocks the activation of the entire classical signaling pathway by inhibiting complement protein C1q, which is upstream of the complement cascade reaction, while also maintaining the functional integrity of other complement pathways. It can be used in studies related to Guillain-Barre Syndrome (GBS). |
| M45389 | Avacincaptad pegol | Avacincaptad pegol is a nucleic acid aptamer and inhibitor of C5 complement that reduces inflammation-associated retinal pigment epithelial (RPE) damage.Avacincaptad pegol caqn be used to study stargardt macular dystrophy (STGD1) and geographic atrophy (GA). |
| M41964 | BR103 | BR103 is a C3aR-specific small molecule ligand. |
| M41963 | 3-Phenoxybenzaldehyde | 3-Phenoxybenzaldehyde has weak complement classical pathway inhibition and hemolytic activity. |
| M41962 | NH2-C6-ARC186 | NH2-C6-ARC186 is a modified ARC186 with NH2-C6 that can be coupled to other peptides or molecules. |
| M41961 | Zilucoplan TFA | Zilucoplan TFA (RA101495) is a 15 amino acid macrocyclic peptide and potent complement component 5 (C5) inhibitor that specifically targets C5, a component of the terminal complement activation pathway, thereby preventing the cleavage of C5 by C5 converting enzyme to complement components C5a and C5b, and thus preventing the downstream assembly and activity of the membrane attack complex (MAC). Can be used in studies related to immune-mediated necrotizing myopathy (IMNM) and generalized myasthenia gravis (gMG). |
| M41960 | Complement C1s-IN-1 | Complement C1s-IN-1 is a potent, selective, orally active and cross the blood-brain barrier C1s inhibitor with an IC50 value of 36 nM. |
| M31313 | Pegcetacoplan | Pegcetacoplan is a polyethylene glycolated peptide and an inhibitor of complement protein C3 that inhibits intravascular and extravascular hemolysis. |
| M31043 | EG01377 dihydrochloride | EG01377 dihydrochloride is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of 609 nM for both NRP1-a1 and NRP1-b1. EG01377 dihydrochloride has antiangiogenic, antimigratory, and antitumor effects. |
| M30679 | 3-O-(2'E,4'Z-Decadienoyl)ingenol | 3-O-(2'E,4'Z-Decadienoyl)ingenol is a natural diterpene that exhibits significant anticomplement activity with an IC50 of 89.5 μM. |
| M29382 | EG01377 | EG01377 is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1), with a Kd of 1.32 μM, and IC50s of both 609 nM for NRP1-a1 and NRP1-b1. EG01377 has antiangiogenic, antimigratory, and antitumor effects. |
| M29009 | Complement factor D-IN-2 | Complement factor D-IN-2 is an inhibitor of complement factor D. Complement factor D-IN-2 targets factor D and inhibits the complement cascade at an early and essential point in the alternative complement pathway. Complement factor D-IN-2 can be used for the research of autoimmune diseases. |
| M28435 | Cemdisiran, terminal sugar modification- | Cemdisiran, terminal sugar modification- is an investigational N-acetylgalactosamine-conjugated RNAi agent. Cemdisiran, a siRNA-targeting C5 mRNA, suppresses liver production of complement component C5. |
| M28401 | AMY-101 | AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation. |
| M28303 | Complement factor D-IN-1 | Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC50s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively. |
| M25232 | Mirococept | Mirococept (APT070) is an antibody targeting to complement system C3b/C4b, as well as a membrane-localizing C3 convertase inhibitor. Mirococept reduces the release of C-peptide and pro-inflammatory cytokines, and reduces the infiltration of inflammatory cells. Mirococept reduces intraislet inflammation, which is beneficial to islet transplantation. Mirococept also inhibits increased intestinal and pulmonary vascular permeability to reduce neutrophil influx. |
| M25170 | Gefurulimab | Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
